Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Evaluation of Resistance Development to the Gwt1 inhibitor Manogepix (APX001A) in Candida Species.

Kapoor M, Moloney M, Soltow QA, Pillar CM, Shaw KJ.

Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01387-19. doi: 10.1128/AAC.01387-19. [Epub ahead of print]

2.

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis.

Wiederhold NP, Najvar LK, Shaw KJ, Jaramillo R, Patterson H, Olivo M, Catano G, Patterson TF.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01120-19. doi: 10.1128/AAC.01120-19. [Epub ahead of print]

3.

Characterizing wing tears in common pipistrelles (Pipistrellus pipistrellus): investigating tear distribution, wing strength, and possible causes.

Khayat ROS, Shaw KJ, Dougill G, Melling LM, Ferris GR, Cooper G, Grant RA.

J Mammal. 2019 Jul 27;100(4):1282-1294. doi: 10.1093/jmammal/gyz081. Epub 2019 Jun 4.

4.

Prevalence of hematologic toxicity from copperhead envenomation: an observational study.

Wills BK, Billet M, Rose SR, Cumpston KL, Counselman F, Shaw KJ, Cresswell KG, Charlton N.

Clin Toxicol (Phila). 2019 Jul 25:1-4. doi: 10.1080/15563650.2019.1644346. [Epub ahead of print]

PMID:
31342795
5.

APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia.

Viriyakosol S, Kapoor M, Okamoto S, Covel J, Soltow QA, Trzoss M, Shaw KJ, Fierer J.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01715-18. doi: 10.1128/AAC.01715-18. Print 2019 Feb.

6.

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis.

Gebremariam T, Alkhazraji S, Alqarihi A, Jeon HH, Gu Y, Kapoor M, Shaw KJ, Ibrahim AS.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01713-18. doi: 10.1128/AAC.01713-18. Print 2019 Feb.

7.

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis.

Zhao Y, Lee MH, Paderu P, Lee A, Jimenez-Ortigosa C, Park S, Mansbach RS, Shaw KJ, Perlin DS.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00425-18. doi: 10.1128/AAC.00425-18. Print 2018 Oct.

8.

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus.

Shaw KJ, Schell WA, Covel J, Duboc G, Giamberardino C, Kapoor M, Moloney M, Soltow QA, Tenor JL, Toffaletti DL, Trzoss M, Webb P, Perfect JR.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18. doi: 10.1128/AAC.00523-18. Print 2018 Aug.

9.

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris.

Hager CL, Larkin EL, Long L, Zohra Abidi F, Shaw KJ, Ghannoum MA.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02319-17. doi: 10.1128/AAC.02319-17. Print 2018 Mar.

10.

The preparation of microfluidic architecture with monolithic materials using a dual porous silica structure.

Birch C, Esfahani MMN, Shaw KJ, Kemp C, Haswell SJ, Dyer C.

Electrophoresis. 2017 Nov;38(22-23):2996-3002. doi: 10.1002/elps.201700225. Epub 2017 Aug 23.

PMID:
28722238
11.

Combining Electro-Osmotic Flow and FTA® Paper for DNA Analysis on Microfluidic Devices.

Wimbles R, Melling LM, Shaw KJ.

Micromachines (Basel). 2016 Jul 14;7(7). pii: E119. doi: 10.3390/mi7070119.

12.

Sample introduction interface for on-chip nucleic acid-based analysis of Helicobacter pylori from stool samples.

Mosley O, Melling L, Tarn MD, Kemp C, Esfahani MM, Pamme N, Shaw KJ.

Lab Chip. 2016 May 24;16(11):2108-15. doi: 10.1039/c6lc00228e.

PMID:
27164181
13.

Analysis of commercial kidney stone probiotic supplements.

Ellis ML, Shaw KJ, Jackson SB, Daniel SL, Knight J.

Urology. 2015 Mar;85(3):517-21. doi: 10.1016/j.urology.2014.11.013.

14.

Sex identification of ancient DNA samples using a microfluidic device.

Shaw KJ, Brown KA, Brown TA, Haswell SJ.

Methods Mol Biol. 2015;1274:93-8. doi: 10.1007/978-1-4939-2353-3_8.

PMID:
25673485
15.

Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.

Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF.

Diagn Microbiol Infect Dis. 2015 Feb;81(2):112-8. doi: 10.1016/j.diagmicrobio.2014.08.011. Epub 2014 Aug 30.

PMID:
25488274
16.

Amicoumacin a inhibits translation by stabilizing mRNA interaction with the ribosome.

Polikanov YS, Osterman IA, Szal T, Tashlitsky VN, Serebryakova MV, Kusochek P, Bulkley D, Malanicheva IA, Efimenko TA, Efremenkova OV, Konevega AL, Shaw KJ, Bogdanov AA, Rodnina MV, Dontsova OA, Mankin AS, Steitz TA, Sergiev PV.

Mol Cell. 2014 Nov 20;56(4):531-40. doi: 10.1016/j.molcel.2014.09.020. Epub 2014 Oct 9.

17.

Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.

Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Denys GA, Goering RV, Shaw KJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6592-8. doi: 10.1128/AAC.03493-14. Epub 2014 Aug 25.

18.

Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.

Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Goering RV, Jenkins SG, Shaw KJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6949-52. doi: 10.1128/AAC.03380-14. Epub 2014 Aug 18.

19.

Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus.

Hensler ME, Jang KH, Thienphrapa W, Vuong L, Tran DN, Soubih E, Lin L, Haste NM, Cunningham ML, Kwan BP, Shaw KJ, Fenical W, Nizet V.

J Antibiot (Tokyo). 2014 Aug;67(8):549-53. doi: 10.1038/ja.2014.36. Epub 2014 Apr 16.

20.

Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.

Lam T, Hilgers MT, Cunningham ML, Kwan BP, Nelson KJ, Brown-Driver V, Ong V, Trzoss M, Hough G, Shaw KJ, Finn J.

J Med Chem. 2014 Feb 13;57(3):651-68. doi: 10.1021/jm401204g. Epub 2014 Jan 16.

PMID:
24428639
21.

Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J.

PLoS One. 2013 Dec 26;8(12):e84409. doi: 10.1371/journal.pone.0084409. eCollection 2013.

22.

Tedizolid for the management of human infections: in vitro characteristics.

Locke JB, Zurenko GE, Shaw KJ, Bartizal K.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Review.

PMID:
24343830
23.

Identifying the targets of aminoacyl-tRNA synthetase inhibitors by primer extension inhibition.

Orelle C, Szal T, Klepacki D, Shaw KJ, Vázquez-Laslop N, Mankin AS.

Nucleic Acids Res. 2013 Aug;41(14):e144. doi: 10.1093/nar/gkt526. Epub 2013 Jun 12.

24.

Integrated RNA extraction and RT-PCR for semi-quantitative gene expression studies on a microfluidic device.

Shaw KJ, Hughes EM, Dyer CE, Greenman J, Haswell SJ.

Lab Invest. 2013 Aug;93(8):961-6. doi: 10.1038/labinvest.2013.76. Epub 2013 May 27.

25.

Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay.

Cunningham ML, Kwan BP, Nelson KJ, Bensen DC, Shaw KJ.

J Biomol Screen. 2013 Oct;18(9):1018-26. doi: 10.1177/1087057113487208. Epub 2013 May 17.

PMID:
23686103
26.

Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.

Teng M, Hilgers MT, Cunningham ML, Borchardt A, Locke JB, Abraham S, Haley G, Kwan BP, Hall C, Hough GW, Shaw KJ, Finn J.

J Med Chem. 2013 Feb 28;56(4):1748-60. doi: 10.1021/jm301756m. Epub 2013 Feb 12.

PMID:
23362938
27.

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.

Tari LW, Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Nix J, Finn J.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1529-36. doi: 10.1016/j.bmcl.2012.11.032. Epub 2012 Dec 5.

PMID:
23352267
28.

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.

Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Nelson K, Brown-Driver V, Castellano A, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Finn J, Tari LW.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1537-43. doi: 10.1016/j.bmcl.2012.11.073. Epub 2012 Dec 8.

PMID:
23294697
29.

Improved DNA extraction efficiency from low level cell numbers using a silica monolith based micro fluidic device.

Kashkary L, Kemp C, Shaw KJ, Greenway GM, Haswell SJ.

Anal Chim Acta. 2012 Oct 31;750:127-31. doi: 10.1016/j.aca.2012.05.019. Epub 2012 May 22.

PMID:
23062434
30.

The oxazolidinones: past, present, and future.

Shaw KJ, Barbachyn MR.

Ann N Y Acad Sci. 2011 Dec;1241:48-70. doi: 10.1111/j.1749-6632.2011.06330.x. Review.

PMID:
22191526
31.

Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05.

Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ.

Antimicrob Agents Chemother. 2012 Jan;56(1):332-40. doi: 10.1128/AAC.05420-11. Epub 2011 Oct 24.

32.

Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.

Li X, Hilgers M, Cunningham M, Chen Z, Trzoss M, Zhang J, Kohnen L, Lam T, Creighton C, G C K, Nelson K, Kwan B, Stidham M, Brown-Driver V, Shaw KJ, Finn J.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5171-6. doi: 10.1016/j.bmcl.2011.07.059. Epub 2011 Jul 23.

PMID:
21831637
33.

Low fitness cost of the multidrug resistance gene cfr.

LaMarre JM, Locke JB, Shaw KJ, Mankin AS.

Antimicrob Agents Chemother. 2011 Aug;55(8):3714-9. doi: 10.1128/AAC.00153-11. Epub 2011 Jun 6.

34.

Development of a real-world direct interface for integrated DNA extraction and amplification in a microfluidic device.

Shaw KJ, Joyce DA, Docker PT, Dyer CE, Greenway GM, Greenman J, Haswell SJ.

Lab Chip. 2011 Feb 7;11(3):443-8. doi: 10.1039/c0lc00346h. Epub 2010 Nov 12.

PMID:
21072429
35.

Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.

Locke JB, Morales G, Hilgers M, G C K, Rahawi S, José Picazo J, Shaw KJ, Stein JL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5352-5. doi: 10.1128/AAC.00714-10. Epub 2010 Sep 13.

36.

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, G C K, Picazo JJ, Im W, Shaw KJ, Stein JL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5337-43. doi: 10.1128/AAC.00663-10. Epub 2010 Sep 13.

37.

Rapid PCR amplification using a microfluidic device with integrated microwave heating and air impingement cooling.

Shaw KJ, Docker PT, Yelland JV, Dyer CE, Greenman J, Greenway GM, Haswell SJ.

Lab Chip. 2010 Jul 7;10(13):1725-8. doi: 10.1039/c000357n. Epub 2010 Apr 23.

PMID:
20414500
38.

Simple practical approach for sample loading prior to DNA extraction using a silica monolith in a microfluidic device.

Shaw KJ, Joyce DA, Docker PT, Dyer CE, Greenman J, Greenway GM, Haswell SJ.

Lab Chip. 2009 Dec 7;9(23):3430-2. doi: 10.1039/b913309g. Epub 2009 Sep 21.

PMID:
19904411
39.

Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Locke JB, Hilgers M, Shaw KJ.

Antimicrob Agents Chemother. 2009 Dec;53(12):5275-8. doi: 10.1128/AAC.01032-09. Epub 2009 Oct 5.

40.

The use of carrier RNA to enhance DNA extraction from microfluidic-based silica monoliths.

Shaw KJ, Thain L, Docker PT, Dyer CE, Greenman J, Greenway GM, Haswell SJ.

Anal Chim Acta. 2009 Oct 12;652(1-2):231-3. doi: 10.1016/j.aca.2009.03.038. Epub 2009 Mar 31.

PMID:
19786185
41.

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Locke JB, Hilgers M, Shaw KJ.

Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.

42.

Development of a bi-functional silica monolith for electro-osmotic pumping and DNA clean-up/extraction using gel-supported reagents in a microfluidic device.

Oakley JA, Shaw KJ, Docker PT, Dyer CE, Greenman J, Greenway GM, Haswell SJ.

Lab Chip. 2009 Jun 7;9(11):1596-600. doi: 10.1039/b820553a. Epub 2009 Mar 11.

PMID:
19458868
43.

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G.

Antimicrob Agents Chemother. 2008 Dec;52(12):4442-7. doi: 10.1128/AAC.00859-08. Epub 2008 Oct 6.

44.

Health care costs associated with changing clinics and "walk-in" deliveries: evidence supporting a regionalized health information network.

Shaw KJ, Gutierrez M, Fridman M, Gregory KD.

Am J Obstet Gynecol. 2008 Jun;198(6):707.e1-8; discussion 707.e8. doi: 10.1016/j.ajog.2008.03.035. Epub 2008 Apr 29.

PMID:
18448082
45.

Overview of whole-genome essentiality analysis.

Shaw KJ.

Methods Mol Biol. 2008;416:3-8. doi: 10.1007/978-1-59745-321-9_1. No abstract available.

PMID:
18392957
46.

Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis.

Kedar GC, Brown-Driver V, Reyes DR, Hilgers MT, Stidham MA, Shaw KJ, Finn J, Haselbeck RJ.

Antimicrob Agents Chemother. 2008 Jun;52(6):2009-13. doi: 10.1128/AAC.01594-07. Epub 2008 Mar 31.

47.

Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.

Ye B, Arnaiz DO, Chou YL, Griedel BD, Karanjawala R, Lee W, Morrissey MM, Sacchi KL, Sakata ST, Shaw KJ, Wu SC, Zhao Z, Adler M, Cheeseman S, Dole WP, Ewing J, Fitch R, Lentz D, Liang A, Light D, Morser J, Post J, Rumennik G, Subramanyam B, Sullivan ME, Vergona R, Walters J, Wang YX, White KA, Whitlow M, Kochanny MJ.

J Med Chem. 2007 Jun 28;50(13):2967-80. Epub 2007 May 31.

PMID:
17536795
48.

Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.

Wiener JJ, Gomez L, Venkatesan H, Santillán A Jr, Allison BD, Schwarz KL, Shinde S, Tang L, Hack MD, Morrow BJ, Motley ST, Goldschmidt RM, Shaw KJ, Jones TK, Grice CA.

Bioorg Med Chem Lett. 2007 May 15;17(10):2718-22. Epub 2007 Mar 6.

PMID:
17382544
49.

Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.

Gomez L, Hack MD, Wu J, Wiener JJ, Venkatesan H, Santillán A Jr, Pippel DJ, Mani N, Morrow BJ, Motley ST, Shaw KJ, Wolin R, Grice CA, Jones TK.

Bioorg Med Chem Lett. 2007 May 15;17(10):2723-7. Epub 2007 Mar 6.

PMID:
17368897
50.

Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis.

Kedar GC, Brown-Driver V, Reyes DR, Hilgers MT, Stidham MA, Shaw KJ, Finn J, Haselbeck RJ.

Antimicrob Agents Chemother. 2007 May;51(5):1708-18. Epub 2007 Mar 5.

Supplemental Content

Support Center